关于在卵巢癌中对多聚ADP-ribose聚合酶抑制剂耐药性的最新情况
Ruihong Dong1,2, Ting Ding1,2, Zhengyu Li1,2
1Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Frontiers in pharmacology
|July 10, 2023
概括
聚基基聚合酶 (PARP) 抑制剂对于治疗卵巢癌至关重要,但面临抗药性. 本综述探讨了抗药性机制和组合策略,以提高治疗疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 卵巢癌是一种普遍存在的生殖系统瘤,在中国的发病率越来越高.
- 聚 ((ADP-ribose) 聚合酶 (PARP) 抑制剂 (PARPi) 向DNA修复酶,对具有同源重组功能障碍的瘤有效.
- PARPi在临床上用于晚期卵巢上皮癌的维持疗法.
研究的目的:
- 审查在卵巢癌中Poly ((ADP-ribose) 聚合酶抑制剂耐药性的基础机制.
- 总结一下基于聚聚合酶抑制剂 (Poly ((ADP-ribose) 聚合酶抑制剂的组合策略的当前进展.
主要方法:
- 关于对Poly (ADP-ribose) 聚合酶抑制剂耐药性的研究的文献综述.
- 对涉及Poly ((ADP-ribose) 聚合酶抑制剂的组合疗法研究的分析.
主要成果:
- 对Poly (ADP-ribose) 聚合酶抑制剂的耐药性是一个日益增长的临床挑战.
- 已经确定了各种内在和获得的抵抗机制.
- 组合策略在克服阻力方面表现有前途.
结论:
- 了解Poly ((ADP-ribose) 聚合酶抑制剂耐药性机制至关重要.
- 开发新的组合疗法对于提高卵巢癌患者治疗结果至关重要.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


